West Pharmaceutical CEO holds 7,850 shares

Initial Form 3 for West Pharmaceutical Services’ President and CEO discloses direct ownership of 7,850 common shares with no reported transactions.

Rhea-AI Filing Summary

WEST PHARMACEUTICAL SERVICES INC (WST) reported the initial beneficial ownership of its President and CEO, Michel Lagarde, on a Form 3. The filing shows he directly holds 7,850 shares of Common Stock as of August 31, 2026. No purchases, sales, or derivative positions are reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lagarde Michel

Role President and CEO

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 7,850 shares (Direct)

Key Figures

Common Stock beneficially owned: 7,850 shares Insider buy transactions reported: 0 Insider sell transactions reported: 0 +1 more

4 metrics

Common Stock beneficially owned 7,850 shares Direct holdings reported for Michel Lagarde following the event dated August 31, 2026

Insider buy transactions reported 0 BuyCount in transaction summary for this Form 3

Insider sell transactions reported 0 SellCount in transaction summary for this Form 3

Holding entries reported 1 Number of holding entries showing positions without a specific buy or sell

Key Terms

Form 3, Common Stock, beneficial ownership

3 terms

Form 3 regulatory

"reported the initial beneficial ownership of its President and CEO on a Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Common Stock financial

"he directly holds 7,850 shares of Common Stock as of August 31, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

beneficial ownership financial

"reported the initial beneficial ownership of its President and CEO"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

What does the Form 3 for WST disclose about Michel Lagarde’s holdings?

The Form 3 reports that Michel Lagarde, President and CEO of WST, directly holds 7,850 shares of Common Stock as of August 31, 2026, with no reported purchases, sales, or derivative positions in this filing.

How many WST shares does Michel Lagarde beneficially own according to this Form 3?

According to the Form 3, Michel Lagarde beneficially owns 7,850 shares of West Pharmaceutical Services Common Stock, held directly, following the event dated August 31, 2026.

Does the WST Form 3 show any recent insider buying or selling by Michel Lagarde?

No. The Form 3 lists Lagarde’s direct ownership of 7,850 shares but shows no insider purchases, sales, or derivative exercises; it is an initial holdings disclosure, not a record of new transactions.

Is Michel Lagarde a ten percent owner of WST based on this Form 3?

No. The reporting information identifies Michel Lagarde as a director and President and CEO of West Pharmaceutical Services, but it does not classify him as a ten percent owner.

Does the WST Form 3 mention any Rule 10b5-1 trading plan for Michel Lagarde?

No. The structured data do not indicate that the reported holdings are associated with a Rule 10b5-1 trading plan; the filing functions solely as an initial statement of beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 03:34 PM Accepted by SEC EDGAR 09/10/2026 - 03:33 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lagarde Michel

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/31/2026

3. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,850	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Louis Lalli, as an agent for Michel Lagarde	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)